Sun Pharma Advanced Research Company Limited reported standalone unaudited financial results for the third quarter and nine months ended December 31, 2016. For the quarter, the company reported loss from operations before other income and finance costs of INR 691.6 million against INR 409.2 million for the same period of last year. Loss before tax was INR 663.3 million against INR 410.2 million for the same period of last year. Loss for the period was INR 663.3 million or INR 2.69 per basic and diluted share against INR 410.2 million or INR 1.73 per basic and diluted share for the same period of last year. Income from operations was INR 230.5 million against INR 335.5 million for the same period of last year. For the nine months, the company reported loss from operations before other income and finance costs of INR 961 million against INR 603.7 million for the same period of last year. Loss before tax was INR 880 million against INR 604.1 million for the same period of last year. Loss for the period was INR 880 million or INR 3.56 per basic and diluted share against INR 604.1 million or INR 2.55 per basic and diluted share for the same period of last year. Income from operations was INR 1,394.2 million against INR 1,201.1 million for the same period of last year.